LON:DXRX Diaceutics (DXRX) Share Price, News & Analysis GBX 134 -0.50 (-0.37%) As of 03:23 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Diaceutics Stock (LON:DXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Diaceutics alerts:Sign Up Key Stats Today's Range 133▼ 13450-Day Range 133▼ 17652-Week Range 121.50▼ 180Volume1,645 shsAverage Volume175,306 shsMarket Capitalization£113.40 millionP/E Ratio1,218.18Dividend YieldN/APrice TargetGBX 215.50Consensus RatingBuy Company Overview At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®. Read More Receive DXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DXRX Stock News HeadlinesDiaceutics Issues Shares Under Employee Incentive Schemes in Latest Block Listing UpdateApril 7, 2026 | tipranks.comDiaceutics Executes Routine Management Share Purchases Under Incentive Plan With No Change to Share CapitalApril 1, 2026 | tipranks.comSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits. | TradeSmith (Ad)Diaceutics Issues New Shares to Trust as PDMRs Participate in Incentive PlanFebruary 3, 2026 | tipranks.comDiaceutics PLC Expands Employee Share Incentive PlanNovember 28, 2025 | tipranks.comDiaceutics PLC Enhances Employee Engagement with Share Incentive PlanNovember 4, 2025 | tipranks.comDiaceutics Enhances Employee Incentives with Share PurchasesOctober 1, 2025 | tipranks.comDiaceutics PLC Expands Share Incentive Plan with New Share IssuanceSeptember 2, 2025 | tipranks.comSee More Headlines DXRX Stock Analysis - Frequently Asked Questions How have DXRX shares performed this year? Diaceutics' stock was trading at GBX 128 at the beginning of the year. Since then, DXRX shares have increased by 4.7% and is now trading at GBX 134. How were Diaceutics' earnings last quarter? Diaceutics PLC (LON:DXRX) issued its quarterly earnings results on Tuesday, May, 26th. The company reported $11.00 EPS for the quarter. The company earned $38.44 million during the quarter. Diaceutics had a net margin of 0.25% and a trailing twelve-month return on equity of 0.25%. How do I buy shares of Diaceutics? Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Diaceutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR). Company Calendar Last Earnings5/26/2026Today7/16/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolLON:DXRX CIKN/A Webwww.diaceutics.com PhoneN/AFaxN/AEmployees151Year FoundedN/APrice Target and Rating Average Price Target for DiaceuticsGBX 215.50 High Price TargetGBX 216 Low Price TargetGBX 215 Potential Upside/Downside+60.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)GBX 0.11 Trailing P/E Ratio1,218.18 Forward P/E Ratio132.57 P/E GrowthN/ANet Income-£2.84 million Net Margins0.25% Pretax MarginN/A Return on Equity0.25% Return on Assets-6.06% Debt Debt-to-Equity Ratio2.85 Current Ratio3.43 Quick Ratio9.92 Sales & Book Value Annual Sales£38.44 million Price / Sales2.95 Cash FlowGBX 42.95 per share Price / Cash Flow3.12 Book ValueGBX 45.87 per share Price / Book2.92Miscellaneous Outstanding Shares84,629,000Free FloatN/AMarket Cap£113.40 million OptionableNot Optionable Beta0.89 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (LON:DXRX) was last updated on 7/17/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Diaceutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
